Reuters logo
RedHill Bio's gastric drug succeeds in late-stage study
2017年6月14日 / 中午12点23分 / 5 个月前

RedHill Bio's gastric drug succeeds in late-stage study

June 14 (Reuters) - Israel-based RedHill Biopharma Ltd said its experimental drug for the treatment of gastroenteritis met the main goal in a late-stage study.

The trial tested the efficacy and safety of the drug, bekinda, versus a placebo, in 321 adults and children over the age of 12.

Gastroenteritis - inflammation of the stomach and intestines that causes vomiting and diarrhea - is a very common illness in the United States, with about 179 million cases annually, the company said. (Reporting by Natalie Grover in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below